Print

Corixa Corporation (CRXA) Announces European Approval For Fendrix, GlaxoSmithKline Biologicals' (GSK) Hepatitis B Vaccine Containing Corixa's MPL Adjuvant 
10/19/2005 5:12:39 PM

SEATTLE--(BUSINESS WIRE)--Feb. 8, 2005--Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced that GlaxoSmithKline Biologicals (GSK Bio) has received European approval for its hepatitis B vaccine, Fendrix(R), containing Corixa's MPL(R) adjuvant.
//-->